Recent Finacing
Recent Raise
Enliven Therapeutics is a precision oncology company designing highly selective tyrosine kinase inhibitors using rapid medicinal-chemistry-driven synthesis to develop candidates for BCR-ABL CML, HER2‑mutant NSCLC, and CNS‑penetrant programs.
